Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARDA Signs Biodefense Contracts With GSK And Soligenix

This article was originally published in The Pink Sheet Daily

Executive Summary

Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.

Advertisement

Related Content

CROs Getting Govt. Support To Help Countermeasure Sponsors
HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion
Deals Of The Week: GlaxoSmithKline/BARDA, Evotec/Roche, F-Star/Merck Serono

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel